Biogen Inc.
NASDAQ: BIIB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher A. Viehbacher
- Employees
- 7,605
- Headquarters
- Cambridge, United States
- IPO year
- 1991
- Market cap
- $29.0B
- Website
- https://www.biogen.com
Loading BIIB…
Loading profile data…Frequently asked questions about BIIB
What does Biogen Inc. (BIIB) do?
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYR...
Where does BIIB trade?
Biogen Inc. (BIIB) trades on the NASDAQ Global Select.
What sector is BIIB in?
Biogen Inc. (BIIB) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Biogen Inc.?
Christopher A. Viehbacher is the chief executive officer of Biogen Inc. (BIIB).
Where is Biogen Inc. headquartered?
Biogen Inc. is headquartered in United States.
Does BIIB pay a dividend?
Biogen Inc. (BIIB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BIIB go public?
Biogen Inc. (BIIB) completed its initial public offering in 1991.